ChartMill assigns a Buy % Consensus number of 86% to AVBP. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-25 | Truist Securities | Initiate | Buy |
| 2025-11-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-08-12 | Citigroup | Maintains | Buy -> Buy |
| 2025-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Reiterate | Buy |
| 2025-06-25 | Clear Street | Initiate | Buy |
| 2025-06-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-24 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-20 | Jones Trading | Initiate | Buy |
| 2025-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-20 | B. Riley Securities | Initiate | Buy |
| 2025-03-10 | Guggenheim | Initiate | Buy |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-11 | Citigroup | Maintains | Buy -> Buy |
| 2024-09-10 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-10 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-15 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-02-20 | Goldman Sachs | Initiate | Buy |
| 2024-02-20 | Citigroup | Initiate | Buy |
| 2024-02-20 | Jefferies | Initiate | Buy |
17 analysts have analysed AVBP and the average price target is 41.17 USD. This implies a price increase of 66.75% is expected in the next year compared to the current price of 24.69.
The consensus rating for ARRIVENT BIOPHARMA INC (AVBP) is 85.8824 / 100 . This indicates that analysts generally have a positive outlook on the stock.